Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Aktis Oncology, Inc.NASDAQ: AKTS
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin at -703.6%
Operating margin was -703.6% in Q1 FY2026.
What to watch
Whether operating margin reaches the consensus estimate from 5 analysts of -681.7% for the fiscal year ending Dec 2026, up from -1149.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -703.6%+225.5 pp QoQ
- Last fiscal yearDec 2025
- -1149.5%+2350.8 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +2350.8 pp | +467.8 pp | -1883.0 pp |
| 3 years | — | -467.1 pp | — |
| 5 years | +989.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1149.5%
- Year-over-year change
- +2350.8pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1149.5% | +2350.8pp |
| FY2024 | 2024-12-31 | -3500.3% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
Operating Margin vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's FY2025 operating margin of -1149.5% is the 4th highest of the 5 companies compared; the peer median is -211.1%.
- Its year-over-year change of +2350.8 pp is the highest of 5, against a peer median of +161.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -7.6% | +6.7 pp | +18.3 pp | |
| LTM Mar 2026 | -40.5% | +24.7 pp | +32.2 pp | |
| LTM Mar 2026 | -381.8% | +583.8 pp | +465.3 pp | |
| FY2025 | -1149.5% | +2350.8 pp | — | |
| FY2025 | -3084.8% | +297.6 pp | — | |
| FY2025 | — | — | — | |
| Peer median (excluding AKTS) | -211.1% | +161.2 pp | +32.2 pp | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 1.49M | 6.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 1.49M | 6.5M |
| Gross Margin | — | — | 100.0% | 100.0% |
| Research & Development | 14.3M | 25.92M | 40.95M | 67.45M |
| Selling, General & Admin | 5.11M | 7.68M | 11.31M | 12.6M |
| Operating Expenses | 19.76M | 34.79M | 53.54M | 81.18M |
| Depreciation & Amortization | 445K | 1.2M | 1.58M | 2.33M |
| EBITDA | (17.48M) | (27.45M) | (42.41M) | (61.4M) |
| EBITDA Margin | — | — | -2851.7% | -945.1% |
| Operating Income | (19.76M) | (34.79M) | (52.05M) | (74.68M) |
| Operating Margin | — | — | -3500.3% | -1149.5% |
| Interest Income | 1.65M | 5.38M | 8.1M | 11.01M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.84M | 6.15M | 8.07M | 10.95M |
| Income Before Tax | (17.93M) | (28.64M) | (43.98M) | (63.73M) |
| Pre-Tax Margin | — | — | -2957.6% | -980.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (17.93M) | (28.64M) | (43.98M) | (63.73M) |
| Net Margin | — | — | -2957.6% | -980.9% |
| EPS (Basic) | (0.51) | (0.82) | (1.26) | (1.19) |
| EPS (Diluted) | (0.51) | (0.82) | (1.26) | (1.19) |
| Weighted Avg Shares | 34.86M | 34.86M | 34.86M | 52.52M |
| Weighted Avg Shares (Diluted) | 34.86M | 34.86M | 34.86M | 52.52M |
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.